Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Turner's Syndrome
Conditions
Turner's Syndrome
Trial Timeline
Apr 1, 2009 → Mar 1, 2011
NCT ID
NCT00870220About Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch is a phase 1 stage product being developed by Novo Nordisk for Turner's Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00870220. Target conditions include Turner's Syndrome.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00870220 | Phase 1 | Terminated |
Competing Products
1 competing product in Turner's Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| r-hGH | Merck | Approved | 85 |